During clinical studies the most frequently reported adverse reactions included headache, nausea, rigors, and dizziness FDA Label. Alternatively, although post-marketing experience has reported the following adverse reactions, the voluntary nature of their reporting means their frequency or possibility of causal relationships to use of the medication cannot be established reliably: infusion reactions (hypersensitivity including anaphylaxis, headache, diarrhea, tachycardia, fever, fatigue, dizziness, malaise, chills, flushing, urticaria or other skin reactions, wheezing or other chest discomforts, nausea, vomiting, rigors, back pain, myalgia, arthralgia, changes in blood pressure), renal reactions (acute renal dysfunction or failure, osmotic nephropathy), respiratory reactions (apnea, acute respiratory distress syndrome ARDS, TRALI, cyanosis, hypoxemia, pulmonary edema, dyspnea, bronchospasm), cardiovascular reactions (cardiac arrest, thromboembolism, vascular collapse, hypotension), neurological reactions (coma, loss of consciousness, seizures, tremor, aseptic meningitis syndrome), integumentary reactions ( Stevens-Johnson syndrome, epidermolysis, erythema multiforme, dermatitis (e.g., bullous dermatitis)), hematologic reactions (pancytopenia, leukopenia, hemolysis, positive direct antiglobulin (Coombs’) test), gastrointestinal reactions (hepatic dysfunction, abdominal pain), and pyrexia FDA Label.